

SURGICAL ONCOLOGY

Theory and Multidisciplinary Practice

SECOND EDITION



EDITED BY
GRAEME POSTON
LYNDA WYLD
RICCARDO A AUDISIO

SECOND
EDITION

Surgical Oncology

Theory and Multidisciplinary Practice



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

SECOND
EDITION

Surgical Oncology

Theory and Multidisciplinary Practice

Edited by

Graeme Poston, DSc MS MBBS FRCS(Eng) FRCS(Ed)

Professor of Surgery, University of Liverpool and Consultant
Hepatobiliary Surgeon, Aintree University Hospital
Liverpool, UK

Lynda Wyld, BMedSci MBChB, PhD, FRCS(Gen Surg)

Reader in Surgical Oncology, University of Sheffield, UK and
Honorary Consultant Oncoplastic Breast Surgeon, Doncaster Royal Infirmary
Doncaster, UK

Riccardo A Audisio, MD FRCS(Eng)

Professor of Surgery, University of Liverpool and Consultant
Breast Surgeon, Whiston and St Helen's Hospital, St Helens
Liverpool, UK



CRC Press

Taylor & Francis Group
Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2017 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper
Version Date: 20160128

International Standard Book Number-13: 978-1-4987-0199-0 (Pack - Book and Ebook)

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional's own judgement, their knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies' and device or material manufacturers' printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

Names: Poston, Graeme J., editor. | Wyld, Lynda, editor. | Audisio, Riccardo A., editor.
Title: Surgical oncology : theory and multidisciplinary practice / [edited by] Graeme J. Poston, Lynda Wyld, Riccardo A. Audisio.
Other titles: Textbook of surgical oncology (Poston)
Description: Second edition. | Boca Raton : CRC Press/Taylor & Francis, 2016. | Preceded by Textbook of surgical oncology / edited by Graeme J. Poston, R. Daniel Beauchamp, Theo J.M. Ruers. 2007. | Includes bibliographical references and index.
Identifiers: LCCN 2016003701 (print) | LCCN 2016003999 (ebook) | ISBN 9781498701990 (hardcover : alk. paper) | ISBN 9781498702003 (e-book) | ISBN 9781498715980 (vital book)
Subjects: | MESH: Neoplasms--surgery | Medical Oncology
Classification: LCC RD651 (print) | LCC RD651 (ebook) | NLM QZ 268 | DDC 616.99/4059--dc23
LC record available at <http://lcn.loc.gov/2016003701>

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

Dedication

Surgical Oncology: Theory and Multidisciplinary Practice, Second Edition, is dedicated to our patients across Europe in the hope that we will not fail them. This textbook has been written by a global multidisciplinary team of cancer

experts from across Europe and beyond in the hope that it will inspire a new generation of surgeons to strive toward best practice and outcomes in cancer surgery.



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Contents

| | |
|---|-------------|
| Foreword | xi |
| Preface | xv |
| Contributors | xvii |
| | |
| PART 1 BASIC PRINCIPLES OF ONCOLOGY | 1 |
| <hr/> | |
| 1 Cancer epidemiology | 3 |
| <i>Gurdeep S Mannu and Sarah C Darby</i> | |
| 2 Genetics and hereditary cancer syndromes, genetic polymorphisms and cancer | 17 |
| <i>D Gareth Evans</i> | |
| 3 Clinical trial design in surgical oncology | 27 |
| <i>Serge Evrard and Pippa Mckelvie-Sebileau</i> | |
| 4 A critical overview of screening for cancer | 33 |
| <i>Karsten Juhl Jørgensen</i> | |
| 5 Principles of radiation therapy for surgeons | 43 |
| <i>Saskia Rademakers, Johan Bussink and Philip Poortmans</i> | |
| 6 Intraoperative radiotherapy | 55 |
| <i>Wojciech P Polkowski and David A L Morgan</i> | |
| 7 Principles of systemic therapy for surgeons | 61 |
| <i>Susana Roselló, Valentina Gambardella, Juan Miguel Cejalvo and Andrés Cervantes</i> | |
| 8 Quality assurance in surgical oncology | 75 |
| <i>Michel W J M Wouters</i> | |
| 9 Palliative care in surgical oncology | 83 |
| <i>Iain Lawrie and Mari Lloyd-Williams</i> | |
| 10 Communication and psychological needs of the cancer surgery patient | 91 |
| <i>Clare Byrne and Graeme J Poston</i> | |
| 11 Nutrition in cancer and cancer surgery | 103 |
| <i>Sergio Sandrucci, Laura Esposito and Marco Braga</i> | |
| 12 Image-guided surgery | 117 |
| <i>Leonora S F Boogerd, Henricus J M Handgraaf, Martin C Boonstra, Alexander L Vahrmeijer and Cornelis J H van de Velde</i> | |
| 13 The role of interventional radiology in the management of cancer patients | 125 |
| <i>Shahzad Ilyas, Tarun Sabharwal and Andy Adam</i> | |
| 14 Minimal access and robotic surgery | 135 |
| <i>Domenico D'ugo, Alberto Biondi and Maria Carmen Lirosi</i> | |
| 15 Surgery for older cancer patients | 149 |
| <i>Ponnandai S Somasundar, Lynda Wyld and Riccardo A Audisio</i> | |
| 16 Cancer of unknown primary | 157 |
| <i>Nicholas Pavlidis</i> | |

| | |
|--|------------|
| PART 2 DISEASE SITE SPECIFIC SURGICAL ONCOLOGY | 163 |
| CANCER OF THE HEAD AND NECK | |
| 17 Oral cancer | 165 |
| <i>Akash Agarwal, Arun Chaturvedi and Sanjeev Misra</i> | |
| 18 Salivary gland tumors | 173 |
| <i>Arun Chaturvedi, Akash Agarwal and Sanjeev Misra</i> | |
| 19 Paranasal sinus cancers | 179 |
| <i>Sameer Gupta, Akash Agarwal and Sanjeev Misra</i> | |
| 20 Skull base tumours | 185 |
| <i>Amit Goyal, Sameer Gupta and Sanjeev Misra</i> | |
| 21 Cancer of larynx and hypopharynx | 191 |
| <i>Dhairyasheel Savant, Tanveer Abdul Majeed, Puneet Pareek, Amit Goyal and Akash Agarwal</i> | |
| BREAST CANCER | |
| 22 Breast cancer | 197 |
| <i>Marjut Leidenius, Lynda Wyld, Isabel T Rubio, Tibor Kovacs, Tuomo Meretoja, Johanna Mattson, Philip Poortmans, Päivi Heikkilä and David Evans</i> | |
| LUNG | |
| 23 Lung and pleura | 249 |
| <i>Michael Shackcloth</i> | |
| GASTROINTESTINAL | |
| 24 Esophageal cancer | 271 |
| <i>Franco Roviello, Karol Polom and Daniele Marrelli</i> | |
| 25 Gastric cancer | 287 |
| <i>William H Allum, Young-Woo Kim, Elisa Fontana, Naureen Starling and Bang Wool Eom</i> | |
| 26 Gastrointestinal stromal tumor | 309 |
| <i>Young-Woo Kim and Ji Yeon Park</i> | |
| 27 Small bowel and appendiceal tumors | 323 |
| <i>Sarah T O'dwyer</i> | |
| 28 Cancer of the colon and rectum | 331 |
| <i>Petra G Boelens, Pieter J Tanis, Gina Brown, Nicholas P West, Cornelis J H van de Velde and Harm J T Rutten</i> | |
| 29 Anal cancer | 383 |
| <i>Per J Nilsson</i> | |
| 30 Peritoneal surface malignancies | 389 |
| <i>Santiago González-Moreno, Paul H Sugarbaker, Gloria Ortega-Pérez, Oscar Alonso-Casado, Dominique Elias, Marcello Deraco, Pompiliu Piso and Kurt van der Speeten</i> | |
| HEPATOBIILIARY | |
| 31 Pancreatic and ampullary cancer | 403 |
| <i>Kulbir Mann, Timothy Gilbert, Frances Oldfield and Paula Ghaneh</i> | |
| 32 Hepatocellular carcinoma | 429 |
| <i>Robert P Jones, Daniel H Palmer and Hassan Z Malik</i> | |
| 33 Carcinoma of the biliary tree and gallbladder | 441 |
| <i>Thomas Gruenberger, Wolfgang Schima, Koert F D Kuhlmann and Birgit Gruenberger</i> | |
| 34 Liver metastases | 453 |
| <i>Michel Rivoire, Serge Evrard and Theo J M Ruers</i> | |
| UROLOGICAL | |
| 35 Renal cell carcinoma | 467 |
| <i>Rogier K van der Vijgh and Theo M de Reijke</i> | |
| 36 Urothelial carcinoma of the bladder and upper tract | 475 |
| <i>Anneke C M Kusters and Theo M de Reijke</i> | |
| 37 Prostate cancer | 485 |
| <i>Lona Vyas and Derek J Rosario</i> | |

| | | |
|-------------|---|------------|
| 38 | Testicular tumours <i>Celine P E Asselbergs and Theo M de Reijke</i> | 501 |
| GYNAECOLOGY | | |
| 39 | Gynaecological oncology <i>Gabriella Ferrandina and Giovanni Scambia</i> | 509 |
| SKIN | | |
| 40 | Skin cancer: Squamous cell carcinoma and basal cell carcinoma <i>Ibrahim Edhemović</i> | 527 |
| 41 | Skin: Melanoma <i>Konstantinos Lasithiotakis, Odysseas Zoras and Charles Balch</i> | 537 |
| ENDOCRINE | | |
| 42 | Thyroid cancer <i>Samira M Sadowski, Xavier M Keutgen and Electron Kebebew</i> | 553 |
| 43 | Adrenal tumours <i>Atul Bagul and Saba Balasubramanian</i> | 565 |
| 44 | Parathyroid cancer <i>Sheila Fraser and Stan Sidhu</i> | 577 |
| 45 | Neuroendocrine tumours of the gastrointestinal tract <i>Menno R Vriens and Inne H M Borel Rinkes</i> | 587 |
| SARCOMA | | |
| 46 | Bone sarcoma <i>Robert J Grimer and Michael Parry</i> | 593 |
| 47 | Extremity soft tissue sarcoma <i>Nicholas C Eastley, Andrew J Hayes and Robert U Ashford</i> | 605 |
| 48 | Retroperitoneal sarcoma <i>Sergio Sandrucci, Silvia Stacchiotti and Alessandro Gronchi</i> | 617 |
| NEUROLOGY | | |
| 49 | Neurosurgical oncology: Neoplasms of the brain and meninges <i>Rachel Grossman and Zvi Ram</i> | 631 |
| | Index | 647 |



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Foreword

THE MULTIDISCIPLINARY CANCER CARE TEAM

It is timely that the European Society of Surgical Oncology (ESSO) gathers highly recognized cancer care professionals to write this outstanding book on surgical oncology with a focus on multidisciplinary practice. Personalized cancer care does involve several different disciplines, and surgery has a central role in both curative and palliative treatment. At early stages of a cancer disease curative surgery is often enough, but at later stages multimodality treatments are mostly preferred and must be considered.

A prerequisite for optimal decision making at the multidisciplinary tumour board is high-quality pretreatment diagnostics. Here as well as for optimal treatment the competence by different cancer specialities is crucial. The radiologists and pathologists have important roles to provide relevant diagnostic information. The surgeon must understand the strengths of other treatment options, and radiation oncologists, medical oncologists and interventionists must know the strengths and weaknesses of the surgical procedures. Only then can a multidisciplinary team deliver quality decisions to benefit patients.

Surgical Oncology: Theory and Multidisciplinary Practice, Second Edition, provides not only residents and specialists in surgery but also other cancer specialities and professions the fundamental knowledge necessary for optimal cancer care.



Peter Naredi
ECCO President

I was delighted to be invited, as a medical oncologist, to provide a foreword to *Surgical Oncology: Theory and Multidisciplinary Practice*, Second Edition, as this reinforces the true spirit of collaboration and multidisciplinary that is now the cornerstone of excellent cancer care across Europe.

As the treatment and care of cancer patients becomes more complex, their optimal management requires the expertise of specialists from many different disciplines, including, but not limited to, surgery, radiation therapy, medical oncology, cancer nursing, pathology and imaging.

This has inevitably led to the development of both a multidisciplinary approach and multidisciplinary teams (MDTs). The advantages of working in an MDT environment include management consistency, coordination and communication, educational opportunities and, potentially, improved outcomes. Despite the fact that cancer treatment given through an MDT is logical and has become the 'standard of care' in many leading cancer centres in the world, it is disappointing to find only scarce evidence showing that such an approach is imperative [1,2].

One of the first studies that clearly showed that the MDT may improve patient outcome was a retrospective study from Scotland [3]. This study was performed following the observation of large differences in the survival outcome of patients with ovarian cancer and showed that management by an MDT at a joint clinic improved patient survival, even after adjustment for other clinical and pathological parameters ($p < 0.001$).

Later, other studies suggested that there is an outcome and survival advantage across the various settings of different cancer sub-specialities, ranging from primary surgery to the palliative treatment of stage IV cancers. However, most of these studies were observational and retrospective in nature [4–8]. In reality, the practical implementation of the MDT demonstrates a paradox in cancer treatment: we demand evidence-based medicine for the individual, but not for general cancer care platforms [6]. Prospective studies demonstrating the already broadly accepted added value of the MDT are desirable, especially in a challenging economic environment.

Breast cancer is one example where the MDT has become imperative, especially for primary early stage treatment. Since the time when the 'Halsted procedure' – involving removal of the entire breast, axillary nodes and chest muscles – was considered the standard and the only treatment modality for breast cancer, major advances have been made.

First, it was shown that adding radiation therapy (RT) to lumpectomy was as effective as a mastectomy and far less disfiguring [9]. Later, the sentinel node biopsy (SNB) procedure, which can spare patients without nodal involvement from axillary lymph node dissection (ALND), was introduced [10]. Recently it has even been shown that patients with a positive SNB can – in some clinical situations – be spared ALND, as long as they receive radiation [11,12].

Radiation treatment has also evolved over time. While post-lumpectomy radiation is standard, the exact indications of post-mastectomy RT are still a matter of controversy. Given the emergence of new RT techniques, current efforts focus on minimizing RT. New techniques such as intense modulation radiotherapy (IMRT), partial breast irradiation (PBI) and intraoperative RT or brachytherapy have become available. However, it is crucial to select the right patients for these modern treatments [13,14].

Systemic treatment decisions for breast cancer are clearly influenced by data gathered from pathology, imaging and surgical procedures. Hormonal therapy is generally provided to treat estrogen receptor (ER) positive tumours, while trastuzumab is given only for HER2 positive tumours [15,17]. Neoadjuvant or adjuvant chemotherapy treatment decisions are also directly influenced by clinical and pathological data gathered by MDT.

Because the various treatment modalities are influenced by each other in the treatment of breast cancer, it is undisputed that all personnel involved in the care of one specific individual should discuss and treat the person in an MDT setting. For example, if the surgeon considers sparing ALND in a patient whose SNB is positive, this will result in a lack of formal nodal staging, which may in turn impact decisions on hormonal and chemotherapy treatment. Moreover, it will require post-surgical RT, which may lead to changes in the timing or modality of reconstructive plastic surgeries.

After MDT discussions, the treating physician can go back to the patient with more solid options to discuss, leading to more confidence in the patient–doctor relationship. Interestingly, in a recent survey, 63% of the investigators from western Europe declared that the MDT was a mandatory part of breast cancer care in their country [18]. Similar conclusions are likely to be reached for the treatment and care of all other cancer types.

Lastly, the MDT is likely to expand in the following years, given the gradual implementation in the clinic of powerful diagnostic technologies such as next-generation sequencing designed to move from ‘precision medicine’ to ‘personalized medicine’. These technologies will call for additional experts – such as geneticists and bioinformaticians – to enrich the MDT. The human being residing within the patient will need to be remembered in all treatment decisions.

Marine Piccart
ECCO Past-President

REFERENCES

1. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? *Lancet Oncol* 2006;7(11):935–43.
2. Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. *J Natl Cancer Inst Monogr* 2010;2010(40):72–80.
3. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. *Br J Cancer* 1994;70(2):363–70.
4. Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. *Br J Cancer* 2005;93(9):977–8.
5. Stephens MR, Lewis WG, Brewster AE, Lord I, Blackshaw GRJC, Hodzovic I, et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. *Dis Esophagus Off J Int Soc Dis Esophagus ISDE* 2006;19(3):164–71.
6. Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, et al. Multidisciplinary team working in cancer: what is the evidence? *BMJ* 2010;340:c951.
7. Coory M, Gkolia P, Yang IA, Bowman RV, Fong KM. Systematic review of multidisciplinary teams in the management of lung cancer. *Lung Cancer Amst Neth* 2008;60(1):14–21.
8. Morris E, Haward RA, Gilthorpe MS, Craigs C, Forman D. The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire’s colorectal cancer patients. *Br J Cancer* 2006;95(8):979–85.
9. Fisher B, Slack NH, Cavanaugh PJ, Gardner B, Ravdin RG. Postoperative radiotherapy in the treatment of breast cancer: results of the NSABP clinical trial. *Ann Surg* 1970;172(4):711–32.
10. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrada S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. *Lancet* 1997;349(9069):1864–7.
11. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. *Lancet Oncol* 2014;15(12):1303–10.
12. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA J Am Med Assoc* 2011;305(6):569–75.
13. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. *Lancet Oncol* 2013;14(13):1269–77.
14. Smith GL, Xu Y, Buchholz TA, Giordano SH, Jiang J, Shih Y-CT, et al. Association between treatment with brachytherapy vs whole-breast irradiation and

- subsequent mastectomy, complications, and survival among older women with invasive breast cancer. *J Am Med Assoc* 2012;307(17):1827–37.
15. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med* 2011;365(14):1273–83.
 16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005;353(16):1659–72.
 17. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 2005;353(16):1673–84.
 18. Saini KS, Taylor C, Ramirez A-J, Palmieri C, Gunnarsson U, Schmoll HJ, et al. Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. *Ann Oncol Off J Eur Soc Med Oncol ESMO* 2012;23(4):853–9.



EUROPEAN SOCIETY OF SURGICAL ONCOLOGY

It is with great pleasure that I have agreed to write a foreword for this textbook, which is the work of the most prestigious group of authors in the field with experience and expertise which are second to none.

This textbook is a must read for any colleague involved in the field of surgical oncology for the following reasons:

- The entire width and depth of the field are covered comprehensively; each chapter has a wealth of scientific and clinical information provided in a clear, robust and fluent way.
- Each topic is covered holistically from the relevant elements of basic science to complex and innovative clinical practice, always enriched with most helpful examples reflecting the experience of the authors and aiming to stimulate the critical thinking of the readers.
- The textbook really focuses on a sound multidisciplinary approach reflecting the overall philosophy of the authors regarding the character of modern practice in surgical oncology. I am confident that the educationally superb way with which this approach is presented in the book will be ‘game changing’ even for those who still believe that they can practice within the narrow boundaries of their own specialty.
- The authors give emphasis to patient-centred care; this is of course of paramount importance for all patients, but even more so for cancer patients. A thorough

analysis of issues related to quality of care, quality of outcomes, and above all, quality of life is clearly evident in the whole book.

- The overall content of the book mirrors the syllabus and core curriculum of the European training requirements in surgical oncology as they have been developed by the Division of Surgical Oncology of the Section of Surgery of the European Union of Medical Specialists (UEMS) and the European Society of Surgical Oncology (ESSO). The textbook is an invaluable tool for the preparation of the relevant European exam in surgical oncology.

As president of the UEMS Section of Surgery, I feel particularly proud that this truly excellent textbook reflects the superb work that has been done over the last few years by the executive and all the members of the UEMS Division of Surgical Oncology in collaboration with ESSO; they have our grateful thanks and most sincere congratulations.

I am sure that all colleagues who are involved in the truly challenging and ever-changing field of surgical oncology will find this textbook a most helpful companion and powerful ally in their day-to-day practice.

Enjoy reading it!

Vassilios Papalois
Imperial College Healthcare NHS Trust
European Union of Medical Specialists



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Preface

Surgery is the oldest form of effective cancer treatment and 60% of people cured of cancer are cured by surgery alone [1]. The diagnosis and treatment of cancer has rapidly evolved over the past quarter of a century, with advances in screening and surveillance, diagnostic accuracy, effective systemic therapies and accuracy of radiation therapies, in addition to those in surgical oncology. Furthermore, for those whose cancer remains incurable, these advances significantly contribute to prolonged good quality of life that can now be frequently measured in years, rather than months. Lastly, the morbidity and mortality risks of these treatments have markedly improved, in particular those associated with the more complex cancer operations.

The advances in cancer surgery over the last 25 years (minimal access surgery, enhanced recovery, anaesthesia and intensive care), associated with better use of perioperative (neoadjuvant, adjuvant and conversion) therapies (systemic and radiation), have led to ever-improving outcomes in terms of both disease-free and overall survival. Furthermore, other medical disciplines allied to surgery, such as interventional radiology and nuclear medicine, now allow us to effectively treat patients previously thought beyond the scope of standard care [2]. This observation is especially true for the elderly, a group in which the majority of cancers occur in western society.

These advances are encapsulated in the application of multidisciplinary: the principle that all disciplines are now essential in the management of patients suffering from cancer. All are equally important, and none pre-eminent. Multidisciplinary team working is now the standard of care in most countries, and a legal requirement in many.

Clinical trials in surgical oncology remain challenging [3]. However, advances in cancer surgery need surgeons who can conduct careful prospective evaluations of new operative techniques and technologies, in addition to the application of new adjunctive therapies to improve operative outcomes. It is, however, essential that surgeons pay meticulous attention

to quality assurance, in particular operative technique, when conducting such studies.

Lastly, the most significant recent advances relate to greater understanding of molecular medicine, in particular the genetic mutational markers of better or worse prognosis, so allowing more appropriate uses of increasingly scarcer resources targeted at those whose potential benefit is greater: the age of precision medicine. We would hope that the next 10 years will see the application of precision surgery to the ever-increasing benefit of our cancer patients.

Lynda Wyld
University of Sheffield Medical School
Sheffield, UK

Riccardo A Audisio
University of Liverpool
St Helens, UK

Graeme J Poston
University of Liverpool
Liverpool, UK

REFERENCES

1. Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. *Nat Rev Clin Oncol* 2015;12(2):115–24.
2. Franklin JM, GebSKI V, Poston GJ, Sharma RA. Clinical trials of interventional oncology—moving from efficacy to outcomes. *Nat Rev Clin Oncol* 2015;12(2):93–104.
3. Evrard S, McKelvie-Sibareu P, van de Velde C, Nordlinger B, Poston G. What can we learn from oncology surgical trials? *Nat Rev Clin Oncol* 2016;13(1):55–62.



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Contributors

Andy Adam

Department of Radiology
London, UK

Akash Agarwal

Department of Surgical Oncology
Dr Ram Manohar Lohia Institute of Medical Sciences
Lucknow, India

William H Allum

Department of Surgery
Royal Marsden NHS Foundation Trust
London, UK

Oscar Alonso-Casado

Department of Surgical Oncology
MD Anderson Cancer Center
Madrid, Spain

Robert U Ashford

East Midlands Sarcoma Service
Department of Orthopaedic Surgery
University Hospitals of Leicester, UK

Celine P E Asselbergs

Department of Urology
Academic Medical Center
Amsterdam, The Netherlands

Riccardo A Audisio

University of Liverpool
St Helens Teaching Hospital
St Helens, UK

Atul Bagul

St George's Hospital
London, UK

Saba Balasubramanian

Sheffield Teaching Hospitals
Sheffield, UK

Charles Balch

Department of Surgery
Division of Surgical Oncology
University of Texas Southwestern Medical Center
Dallas, Texas, USA

Alberto Biondi

Department of Surgery
'A. Gemelli' Hospital
Università Cattolica del Sacro Cuore
Rome, Italy

Petra G Boelens

Department of Surgery
Leiden University Medical Center
Leiden, The Netherlands

Leonora S F Boogerd

Department of Surgery
Leiden University Medical Center
Leiden, The Netherlands

Martin C Boonstra

Department of Surgery
Leiden University Medical Center
Leiden, The Netherlands

Inne H M Borel Rinkes

Department of Surgery
University Medical Center Utrecht
Utrecht, The Netherlands

Marco Braga

Department of Surgery
San Raffaele Hospital
Milan, Italy

Gina Brown

Royal Marsden NHS Foundation Trust
and
Department of Radiology
Imperial College London
London, UK

Johan Bussink

Department of Radiation Oncology
Radboud University Medical Centre
Nijmegen, The Netherlands

Clare Byrne

University Hospital Aintree
Liverpool, UK

Juan Miguel Cejalvo

Department of Hematology and Medical Oncology
Biomedical Research Institute INCLIVA
University of Valencia
Valencia, Spain

Andrés Cervantes

Department of Hematology and Medical Oncology
Biomedical Research Institute INCLIVA
University of Valencia
Valencia, Spain

Arun Chaturvedi

Department of Surgical Oncology
Dr Ram Manohar Lohia Institute of Medical Sciences
Lucknow, India

Sarah C Darby

Clinical Trial Service Unit
Nuffield Department of Population Health
University of Oxford
Oxford, UK

Marcello Deraco

Colorectal Unit, Responsible, Peritoneal Malignancies
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy

Theo M de Reijke

Department of Urology
Academic Medical Center
Amsterdam, The Netherlands

Domenico D'Ugo

Department of Surgery
'A. Gemelli' Hospital
Università Cattolica del Sacro Cuore
Rome, Italy

Nicholas C Eastley

East Midlands Sarcoma Service
Department of Orthopaedic Surgery
University Hospitals of Leicester, UK

Ibrahim Edhemović

Department of Surgical Oncology
Institute of Oncology Ljubljana
Ljubljana, Slovenia

Dominique Elias

Department of Surgical Oncology
Institut Gustave Roussy
Villejuif, France

Bang Wool Eom

Center for Gastric Cancer and Department of Surgery
Research institute and Hospital
National Cancer Centre
Goyang, Republic of Korea

Laura Esposito

Visceral Sarcoma Unit
Department of Surgery
San Giovanni Battista Hospital
University of Turin
Torino, Italy

David Evans

Department of Radiology
King's College Hospital
London, UK

Serge Evrard

Department of Surgery
Bergonie Institute
Bordeaux, France

Gabriella Ferrandina

Department of Gynecology/Obstetrics
Catholic University
Rome, Italy

Elisa Fontana

Department of Medicine
Royal Marsden NHS Foundation Trust
London, UK

Sheila Fraser

Royal North Shore Hospital
Sydney, Australia

Valentina Gambardella

Department of Hematology and Medical Oncology
Biomedical Research Institute INCLIVA
University of Valencia
Valencia, Spain

D Gareth Evans

Department of Genomic Medicine
Institute of Human Development
St Mary's Hospital
University of Manchester
Manchester, UK

Paula Ghaneh

Department of Molecular and Clinical Cancer Medicine
University of Liverpool
Liverpool, UK

Timothy Gilbert

Department of Molecular and Clinical Cancer Medicine
University of Liverpool
Liverpool, UK

Santiago González-Moreno

Peritoneal Surface Oncology Program
Department of Surgical Oncology
MD Anderson Cancer Center
Madrid, Spain

Amit Goyal

Department of Otorhinolaryngology
All India Institute of Medical Sciences
Jodhpur, India

Robert J Grimer

Royal Orthopaedic Hospital
Birmingham, UK

Alessandro Gronchi

Sarcoma Unit
Department of Surgery
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy

Rachel Grossman

Department of Neurosurgery
Tel Aviv Medical Center
Sackler Faculty of Medicine
Tel Aviv University
Tel Aviv, Israel

Birgit Gruenberger

Department of Internal Medicine
Hospital of St John of God
Vienna, Austria

Thomas Gruenberger

Department of Surgery
Rudolfstiftung Hospital
Vienna, Austria

Sameer Gupta

Department of Surgical Oncology
King George's Medical University
Lucknow, India

Henricus J M Handgraaf

Department of Surgery
Leiden University Medical Center
Leiden, The Netherlands

Andrew J Hayes

Department of Surgical Oncology
The Royal Marsden NHS Foundation Trust
London, UK

Päivi Heikkilä

Department of Pathology
Helsinki University Hospital
Helsinki, Finland

Shahzad Ilyas

Department of Radiology
Consultant Interventional Radiologist
Guy's and St Thomas' Hospital Trust
London, UK

Robert P Jones

School of Cancer Studies
Institute of Translational Medicine
University of Liverpool
and
Liverpool Hepatobiliary Centre
Aintree University Hospital
Liverpool, UK

Karsten Juhl Jørgensen

The Nordic Cochrane Centre
Rigshospitalet
Copenhagen, Denmark

Electron Kebebew

Endocrine Oncology Branch
National Cancer Institute
National Institutes of Health
Bethesda, Maryland, USA

Xavier M Keutgen

Endocrine Oncology Branch
National Cancer Institute
National Institutes of Health
Bethesda, Maryland, USA

Young-Woo Kim

Center for Gastric Cancer and Department of Surgery
Research Institute and Hospital
National Cancer Centre
Goyang, Republic of Korea

Tibor Kovacs

Guy's and St Thomas' NHS Foundation Trust
London, UK

Koert F D Kuhlmann

Department of Surgical Oncology
Antoni van Leeuwenhoek – Netherlands Cancer Institute
Amsterdam, The Netherlands

Anneke C M Kusters

Department of Urology
Academic Medical Center
Amsterdam, The Netherlands

Konstantinos Lasithiotakis

Department of General Surgery
York Teaching Hospital
NHS Foundation Trust
London, UK

Iain Lawrie

Consultant and Honorary Clinical Senior Lecturer in
Palliative Medicine
The Pennine Acute Hospitals NHS Trust
The University of Manchester, UK

Marjut Leidenius

Department of Breast Surgery
Comprehensive Cancer Centre
Helsinki University Hospital
Helsinki, Finland

Maria Carmen Lirosi

Department of Surgery
'A. Gemelli' Hospital
Università Cattolica del Sacro Cuore
Rome, Italy

Mari Lloyd-Williams

Professor and Honorary Consultant in Palliative Medicine
Academic Palliative and Supportive Care Studies Group
(APSCSG)
Institute Psychology, Health and Society University of
Liverpool, UK

Tanveer Abdul Majeed

Department of Surgical Oncology
Asian Cancer Institute
Mumbai, India

Hassan Z Malik

Liverpool Hepatobiliary Centre
Aintree University Hospital
Liverpool, UK

Kulbir Mann

Department of Molecular and Clinical Cancer Medicine
University of Liverpool
Liverpool, UK

Gurdeep S Mannu

Clinical Trial Service Unit
Nuffield Department of Population Health
University of Oxford
Oxford, UK

Daniele Marrelli

Department of Human Pathology and Oncology Unit of
Surgical Oncology
University of Siena
Siena, Italy

Johanna Mattson

Department of Solid Tumours
Comprehensive Cancer Centre
Helsinki University Hospital
Helsinki, Finland

Pippa McKelvie-Sebileau

Institut Bergonie
Bordeaux, France

Tuomo Meretoja

Comprehensive Cancer Centre
Helsinki University Hospital
Helsinki, Finland

Sanjeev Misra

Department of Surgical Oncology
All India Institute of Medical Sciences
Jodhpur, India

David A L Morgan

Department of Clinical Oncology (Retd.)
Nottingham University Hospitals
Nottingham, UK

Per J Nilsson

Division of Coloproctology
Center for Digestive Diseases
Karolinska University Hospital
Stockholm, Sweden

Sarah T O'Dwyer

Consultant Surgeon
The Colorectal and Peritoneal Oncology Centre
The Christie Hospital NHSFT
Manchester, UK

Frances Oldfield

Department of Molecular and Clinical Cancer Medicine
University of Liverpool
Liverpool, UK

Gloria Ortega-Pérez

Department of Surgical Oncology
Peritoneal Surface Oncology Program
MD Anderson Cancer Center
Madrid, Spain

Daniel H Palmer

School of Cancer Studies
Institute of Translational Medicine
University of Liverpool
and
Liverpool Hepatobiliary Centre
Aintree University Hospital
Liverpool, UK

Puneet Pareek

Department of Radiation Oncology
All India Institute of Medical Sciences
Jodhpur, India

Ji Yeon Park

Center for Gastric Cancer and Department of Surgery
Research Institute and Hospital
National Cancer Center
Goyang, Republic of Korea

Michael Parry

Royal Orthopaedic Hospital
Birmingham, UK

Nicholas Pavlidis

Department of Medical Oncology
Medical School
University of Ioannina
Ioannina, Greece

Pompiliu Piso

Department of Surgery
Klinik für Allgemein- und Viszeralchirurgie
Krankenhaus Barmherzige Brüder Regensburg
Regensburg, Germany

Wojciech P Polkowski

Department of Surgical Oncology
Medical University of Lublin
Lublin, Poland

Karol Polom

Department of Human Pathology and Oncology
Unit of Surgical Oncology
University of Siena
Siena, Italy

Philip Poortmans

Department of Radiation Oncology
Radboud University Medical Center
Nijmegen, The Netherlands

Graeme J Poston

School of Cancer Studies
University of Liverpool
University Hospital Aintree
Liverpool, UK

Saskia Rademakers

Department of Radiation Oncology
Radboud University Medical Center
Nijmegen, The Netherlands

Zvi Ram

Department of Neurosurgery
Tel Aviv Medical Center
Sackler Faculty of Medicine
Tel Aviv University
Tel Aviv, Israel

Michel Rivoire

Department of Surgery
Leon Berard Cancer Center
Lyon, France

Derek J Rosario

University of Sheffield
Royal Hallamshire Hospital
Sheffield, UK

Susana Roselló

Department of Hematology and Medical Oncology
Biomedical Research Institute INCLIVA
University of Valencia
Valencia, Spain

Franco Roviello

Department of Human Pathology and Oncology
Unit of Surgical Oncology
University of Siena
Siena, Italy

Isabel T Rubio

Breast Cancer Centre
Hospital Universitari Vall d'Hebron
Barcelona, Spain

Theo J M Ruers

Netherlands Cancer Institute
Amsterdam, The Netherlands

Harm J T Rutten

School of Oncology and Developmental Biology
University of Maastricht, Maastricht
and

Catharina Hospital Eindhoven
Eindhoven, The Netherlands

Tarun Sabharwal

Department of Radiology
Consultant Interventional Radiologist
Guy's and St Thomas' Hospital Trust
London, UK

Samira M Sadowski

Endocrine Oncology Branch
National Cancer Institute
National Institutes of Health
Bethesda, Maryland, USA
and
Thoracic and Endocrine Surgery
University Hospitals of Geneva
Geneva, Switzerland

Sergio Sandrucci

Visceral Sarcoma Unit
Department of Surgery
San Giovanni Battista Hospital
University of Turin Cso Dogliortti
Torino, Italy

Dhairyasheel Savant

Department of Surgical Oncology
Asian Cancer Institute
Mumbai, India

Giovanni Scambia

Department of Gynecology/Obstetrics
Catholic University
Rome, Italy

Wolfgang Schima

Department of Diagnostic and Interventional Radiology
Krankenhaus Göttlicher Heiland
Krankenhaus der Barmherzigen Schwestern
and
Sankt Josef-Krankenhaus
Vienna, Austria

Michael Shackcloth

Liverpool Heart and Chest Hospital
Liverpool, UK

Stan Sidhu

University of Sydney Endocrine Surgical Unit
Royal North Shore Hospital
Sydney, Australia

Ponnandai S Somasundar

Department of Surgery
Roger Williams Medical Center
Boston University
Providence, Rhode Island, USA

Silvia Stacchiotti

Sarcoma Unit
Department of Cancer Medicine
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy

Naureen Starling

Department of Medicine
Royal Marsden NHS Foundation Trust
London, UK

Paul H Sugarbaker

Program in Peritoneal Surface Oncology
Center for Gastrointestinal Malignancies
MedStar Washington Hospital Center
Washington, DC, USA

Pieter J Tanis

Department of Surgery
Academic Medical Centre
Amsterdam, The Netherlands

Alexander L Vahrmeijer

Department of Surgery
Leiden University Medical Center
Leiden, The Netherlands

Kurt van der Speeten

Department of Surgical Oncology
Ziekenhuis Oost-Limburg
Universiteit Hasselt
and

Department of Life Sciences
BIOMED Research Institute
Oncology Research Cluster
Genk, Belgium

Cornelis J H van de Velde

Department of Surgical Oncology
Leiden University Medical Center
Leiden, The Netherlands

Rogier K van der Vijgh

Department of Urology
Academic Medical Center
Amsterdam, The Netherlands

Menno R Vriens

Department of Surgery
University Medical Center Utrecht
Utrecht, The Netherlands

Lona Vyas

Department of Urology
Royal Hallamshire Hospital
Sheffield, UK

Nicholas P West

Pathology and Tumour Biology
Leeds Institute of Cancer and Pathology
St James's University Hospital
Leeds, UK

Michel W J M Wouters

Department of Surgical Oncology
Netherlands Cancer Institute- Antoni van Leeuwenhoek
Amsterdam, The Netherlands

Lynda Wyld

University of Sheffield Medical School
Sheffield, UK

Odysseas Zoras

Department of Surgical Oncology
University Hospital of Heraklion
Crete, Greece

Basic principles of oncology

| | | |
|-----------|---|------------|
| 1 | Cancer epidemiology | 3 |
| | <i>Gurdeep S Mannu and Sarah C Darby</i> | |
| 2 | Genetics and hereditary cancer syndromes, genetic polymorphisms and cancer | 17 |
| | <i>D Gareth Evans</i> | |
| 3 | Clinical trial design in surgical oncology | 27 |
| | <i>Serge Evrard and Pippa Mckelvie-Sebileau</i> | |
| 4 | A critical overview of screening for cancer | 33 |
| | <i>Karsten Juhl Jørgensen</i> | |
| 5 | Principles of radiation therapy for surgeons | 43 |
| | <i>Saskia Rademakers, Johan Bussink and Philip Poortmans</i> | |
| 6 | Intraoperative radiotherapy | 55 |
| | <i>Wojciech P Polkowski and David A L Morgan</i> | |
| 7 | Principles of systemic therapy for surgeons | 61 |
| | <i>Susana Roselló, Valentina Gambardella, Juan Miguel Cejalvo and Andrés Cervantes</i> | |
| 8 | Quality assurance in surgical oncology | 75 |
| | <i>Michel W J M Wouters</i> | |
| 9 | Palliative care in surgical oncology | 83 |
| | <i>Iain Lawrie and Mari Lloyd-Williams</i> | |
| 10 | Communication and psychological needs of the cancer surgery patient | 91 |
| | <i>Clare Byrne and Graeme J Poston</i> | |
| 11 | Nutrition in cancer and cancer surgery | 103 |
| | <i>Sergio Sandrucci, Laura Esposito and Marco Braga</i> | |
| 12 | Image-guided surgery | 117 |
| | <i>Leonora S F Boogerd, Henricus J M Handgraaf, Martin C Boonstra, Alexander L Vahrmeijer and Cornelis J H van de Velde</i> | |
| 13 | The role of interventional radiology in the management of cancer patients | 125 |
| | <i>Shahzad Ilyas, Tarun Sabharwal and Andy Adam</i> | |
| 14 | Minimal access and robotic surgery | 135 |
| | <i>Domenico D'ugo, Alberto Biondi and Maria Carmen Lirosi</i> | |
| 15 | Surgery for older cancer patients | 149 |
| | <i>Ponnandai S Somasundar, Lynda Wyld and Riccardo A Audisio</i> | |
| 16 | Cancer of unknown primary | 157 |
| | <i>Nicholas Pavlidis</i> | |



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>